Advaxis, Inc. (ADXS)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -48.07 Million USD | -234.79% |
| 2022 | -14.35 Million USD | 19.61% |
| 2021 | -17.86 Million USD | 32.52% |
| 2020 | -26.46 Million USD | -48.77% |
| 2019 | -17.79 Million USD | 73.25% |
| 2018 | -66.51 Million USD | 28.81% |
| 2017 | -93.43 Million USD | -27.03% |
| 2016 | -73.55 Million USD | -56.4% |
| 2015 | -47.03 Million USD | -184.6% |
| 2014 | -16.52 Million USD | 17.32% |
| 2013 | -19.98 Million USD | -65.6% |
| 2012 | -12.06 Million USD | -48.72% |
| 2011 | -8.11 Million USD | 24.94% |
| 2010 | -10.81 Million USD | -1263.55% |
| 2009 | 929.24 Thousand USD | 117.16% |
| 2008 | -5.41 Million USD | -120.68% |
| 2007 | -2.45 Million USD | 60.4% |
| 2006 | -6.19 Million USD | -243.22% |
| 2005 | -1.8 Million USD | -235.6% |
| 2004 | -538.07 Thousand USD | -5280.76% |
| 2003 | -10 Thousand USD | 0.0% |
| 2002 | -10 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -7.33 Million USD | 15.63% |
| 2023 Q4 | -24.67 Million USD | -236.19% |
| 2023 FY | -48.07 Million USD | -234.79% |
| 2023 Q1 | -7.36 Million USD | 23.23% |
| 2023 Q2 | -8.69 Million USD | -18.18% |
| 2022 Q1 | -2.44 Million USD | -803.7% |
| 2022 Q2 | -6.63 Million USD | -171.93% |
| 2022 FY | -14.35 Million USD | 19.61% |
| 2022 Q4 | -9.58 Million USD | -93.15% |
| 2022 Q3 | -4.96 Million USD | 25.18% |
| 2021 Q1 | -9.56 Million USD | -1.81% |
| 2021 Q3 | -5.44 Million USD | 49.78% |
| 2021 FY | -17.86 Million USD | 32.52% |
| 2021 Q4 | -270 Thousand USD | 95.04% |
| 2021 Q2 | -10.84 Million USD | -13.3% |
| 2020 Q2 | -6.71 Million USD | -1.73% |
| 2020 Q4 | -9.39 Million USD | -45.48% |
| 2020 FY | -26.46 Million USD | -48.77% |
| 2020 Q1 | -6.59 Million USD | -21.67% |
| 2020 Q3 | -6.46 Million USD | 3.75% |
| 2019 Q2 | -3.78 Million USD | -6.89% |
| 2019 Q1 | -3.53 Million USD | -127.61% |
| 2019 Q3 | -5.04 Million USD | -33.41% |
| 2019 FY | -17.79 Million USD | 73.25% |
| 2019 Q4 | -5.42 Million USD | -7.45% |
| 2018 Q3 | -18.59 Million USD | -32.68% |
| 2018 Q1 | -13.4 Million USD | 34.58% |
| 2018 FY | -66.51 Million USD | 28.81% |
| 2018 Q4 | 12.81 Million USD | 168.92% |
| 2018 Q2 | -14.01 Million USD | -4.55% |
| 2017 FY | -93.43 Million USD | -27.03% |
| 2017 Q1 | -20.46 Million USD | -19.83% |
| 2017 Q2 | -32.62 Million USD | -59.4% |
| 2017 Q4 | -20.49 Million USD | 11.9% |
| 2017 Q3 | -23.26 Million USD | 28.7% |
| 2016 Q2 | -16.48 Million USD | -6.21% |
| 2016 FY | -73.55 Million USD | -56.4% |
| 2016 Q4 | -17.08 Million USD | 21.3% |
| 2016 Q3 | -21.7 Million USD | -31.64% |
| 2016 Q1 | -15.52 Million USD | 21.78% |
| 2015 Q4 | -19.84 Million USD | -57.75% |
| 2015 FY | -47.03 Million USD | -184.6% |
| 2015 Q2 | -13.56 Million USD | 2.12% |
| 2015 Q3 | -12.57 Million USD | 7.24% |
| 2015 Q1 | -13.85 Million USD | -96.98% |
| 2014 Q4 | -7.03 Million USD | -116.82% |
| 2014 Q1 | -2.31 Million USD | 55.38% |
| 2014 FY | -16.52 Million USD | 17.32% |
| 2014 Q3 | -3.24 Million USD | 43.87% |
| 2014 Q2 | -5.77 Million USD | -149.68% |
| 2013 FY | -19.98 Million USD | -65.6% |
| 2013 Q4 | -5.18 Million USD | 29.96% |
| 2013 Q3 | -7.4 Million USD | -364.32% |
| 2013 Q1 | -5.27 Million USD | 7.55% |
| 2013 Q2 | -1.59 Million USD | 69.77% |
| 2012 Q3 | -1.99 Million USD | 35.9% |
| 2012 Q4 | -5.7 Million USD | -186.83% |
| 2012 FY | -12.06 Million USD | -48.72% |
| 2012 Q1 | -2.4 Million USD | 36.03% |
| 2012 Q2 | -3.1 Million USD | -29.27% |
| 2011 Q2 | 3.64 Million USD | 137.79% |
| 2011 FY | -8.11 Million USD | 24.94% |
| 2011 Q4 | -3.75 Million USD | -30.44% |
| 2011 Q1 | -9.63 Million USD | -1373.4% |
| 2011 Q3 | -2.87 Million USD | -179.05% |
| 2010 Q2 | 2.05 Million USD | 122.51% |
| 2010 Q1 | -9.13 Million USD | -124.81% |
| 2010 Q3 | 323.94 Thousand USD | -84.24% |
| 2010 Q4 | 756.66 Thousand USD | 133.58% |
| 2010 FY | -10.81 Million USD | -1263.55% |
| 2009 FY | 929.24 Thousand USD | 117.16% |
| 2009 Q4 | -4.06 Million USD | -396.87% |
| 2009 Q2 | 172.14 Thousand USD | 121.71% |
| 2009 Q1 | -792.93 Thousand USD | -535.69% |
| 2009 Q3 | 1.36 Million USD | 694.72% |
| 2008 Q2 | -1.23 Million USD | 23.34% |
| 2008 Q4 | 181.99 Thousand USD | 115.53% |
| 2008 Q3 | -1.17 Million USD | 5.02% |
| 2008 Q1 | -1.6 Million USD | -14.82% |
| 2008 FY | -5.41 Million USD | -120.68% |
| 2007 Q2 | 1.11 Million USD | 135.66% |
| 2007 Q3 | -399.99 Thousand USD | -135.77% |
| 2007 Q4 | -1.4 Million USD | -250.41% |
| 2007 FY | -2.45 Million USD | 60.4% |
| 2007 Q1 | -3.13 Million USD | -8367.58% |
| 2006 Q4 | -37.03 Thousand USD | 99.01% |
| 2006 Q1 | -1.3 Million USD | -185.2% |
| 2006 FY | -6.19 Million USD | -243.22% |
| 2006 Q2 | -683.27 Thousand USD | 47.71% |
| 2006 Q3 | -3.74 Million USD | -448.79% |
| 2005 Q4 | -458.13 Thousand USD | 0.04% |
| 2005 Q3 | -458.32 Thousand USD | -17.94% |
| 2005 Q1 | -713.5 Thousand USD | -190.81% |
| 2005 FY | -1.8 Million USD | -235.6% |
| 2005 Q2 | -388.6 Thousand USD | 45.54% |
| 2004 Q4 | -245.35 Thousand USD | 0.0% |
| 2004 FY | -538.07 Thousand USD | -5280.76% |
| 2003 FY | -10 Thousand USD | 0.0% |
| 2002 FY | -10 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -3499.737% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -588.431% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 190.738% |
| Nascent Biotech, Inc. | -2.08 Million USD | -2202.65% |
| Rebus Holdings, Inc. | -1.02 Million USD | -4612.941% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 173.806% |
| Qrons Inc. | -789.34 Thousand USD | -5990.097% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -7501.434% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 23.206% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -11470.26% |
| Skye Bioscience, Inc. | -37.64 Million USD | -27.699% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 35.872% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -631.01% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -17482.9% |
| SQZ Biotechnologies Company | -79.46 Million USD | 39.505% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -1562.014% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -2540.553% |
| Mesoblast Limited | -87.95 Million USD | 45.345% |
| Marizyme, Inc. | -65.34 Million USD | 26.436% |
| Genus plc | 7.9 Million USD | 708.506% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -341.362% |
| Pharming Group N.V. | -10.54 Million USD | -355.745% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -2115.489% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -1195.66% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -443.555% |
| ContraFect Corporation | -65.15 Million USD | 26.217% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -883.86% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -2682.822% |
| IMV Inc. | -36.48 Million USD | -31.756% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -496.45% |
| MultiCell Technologies, Inc. | -380.07 USD | -12648096.385% |
| ONE Bio Corp. | 8.67 Million USD | 654.041% |
| Accustem Sciences Inc. | -3.74 Million USD | -1183.145% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 7.003% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -3693.758% |
| Q BioMed Inc. | -2.05 Million USD | -2242.584% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -1187.758% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -1919.094% |
| Biomind Labs Inc. | -1.21 Million USD | -3858.762% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 19.512% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -1449.826% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -508.268% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -2366.181% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -320893.59% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -202.884% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -726.369% |
| GB Sciences, Inc. | -1.36 Million USD | -3430.353% |
| Alpha Cognition Inc. | -13.77 Million USD | -249.042% |
| HST Global, Inc. | -146.21 Thousand USD | -32778.736% |
| CSL Limited | 2.64 Billion USD | 101.82% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -2639.503% |
| Halberd Corporation | -79.67 Thousand USD | -60234.354% |
| Enzolytics Inc. | -2.17 Million USD | -2108.347% |
| Agentix Corp. | -1.37 Million USD | -3398.153% |
| Resverlogix Corp. | -3.61 Million USD | -1231.634% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -1415.78% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 83.707% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 49153.061% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 794.221% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -1109.969% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -1488.561% |
| AVAX Technologies, Inc. | -6.41 Million USD | -649.527% |
| Zenith Capital Corp. | -10.59 Million USD | -353.681% |
| Genscript Biotech Corporation | -95.47 Million USD | 49.651% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -206732.458% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -1059.497% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -79435.928% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -2297.468% |
| Kadimastem Ltd | -3.3 Million USD | -1353.469% |
| Helix BioMedix, Inc. | -1.05 Million USD | -4452.027% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -1158.759% |
| BioStem Technologies, Inc. | -8.48 Million USD | -466.687% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -10791.567% |
| LadRx Corporation | 400.44 Thousand USD | 12104.705% |
| Cell Source, Inc. | -5.32 Million USD | -803.403% |
| Regen BioPharma, Inc. | 1.02 Million USD | 4796.788% |
| Regen BioPharma, Inc. | 1.02 Million USD | 4796.788% |
| NovAccess Global Inc. | -4.76 Million USD | -907.971% |
| Affymax, Inc. | -14.42 Million USD | -233.278% |
| Itoco Inc. | -1.86 Million USD | -2472.078% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -982.085% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -2780.288% |
| Mobile Lads Corp. | -2.26 Million USD | -2023.986% |
| CytoDyn Inc. | -49.84 Million USD | 3.549% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -60725.225% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -20972.473% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -5005.738% |
| SYBLEU INC | -180.3 Thousand USD | -26561.638% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -2880.771% |
| International Stem Cell Corporation | -131 Thousand USD | -36596.183% |
| Bioxytran, Inc. | -4.28 Million USD | -1023.177% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -88476.061% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -1799.894% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -2173.983% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -6056.076% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -1417.424% |
| Neutra Corp. | -233.46 Thousand USD | -20490.667% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -136.913% |
| PureTech Health plc | -65.69 Million USD | 26.828% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -126.045% |
| IXICO plc | -1.17 Million USD | -3980.815% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -384.255% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 15.852% |
| CSL Limited | 2.64 Billion USD | 101.82% |
| Cellectis S.A. | -103.17 Million USD | 53.407% |